Mrmain. Granowitz in the CC has already acknowledged that the placebo rate will be approximately 5% ( Co had previously stated that it could be as low as 5.2% )
Gabors response ( from memory ) was. ..." approx 5% could be anywhere between 4% and 6% ."...but I think Granowitz is skilled enough in modeling to be pretty accurate given the data they have access to .
Re the trial . As I stated earlier in my reply to Tas.....IMHO US patients in R-IT , especially diabetics , have access to new drugs ..Jardiance for example ...that show CV significant risk reduction .
So imagine if you are a 65 yr old US diabetic with 2 stents enrolled in R-IT . After the trial is not stopped at Interim 2 , you meet with your Cardiologist who explains that he was now prescribing Jardiance to high risk diabetics like you.
He explains that the risk reduction is over 30% over a 3- 4 yr follow up ( from memory ) for patients like you.
So do you add Jardiance and try and stay in R-IT
Drop out of the trial so you can add Jardiance
Reject Jardiance and stay in R-IT even tho theres a 50% chance you getting the placebo.
If you add Jardiance and stay in R-IT , or drop out ...IMHO takes longer to hit the final event ...and thats what we are seeing
JMO
Kiwi
News 
Market Data 
Discover 
